Advanced search
1 file | 740.93 KB

Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model

(2011) PHARMACEUTICAL RESEARCH. 28(7). p.1653-1660
Author
Organization
Project
Ghent researchers on unfolded proteins in inflammatory disease (GROUP-ID)
Abstract
To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-beta-cyclodextrin (Pac/RAME-beta-CD) versus TaxolA (R) at normo- and hyperthermic conditions in rats. Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment. PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-beta-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with TaxolA (R) did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia. Monitoring tumour growth via PET and MRI indicated that Pac/RAME-beta-CD inclusion complexes had a significantly higher efficacy compared to TaxolA (R) in a rat model for peritoneal carcinomatosis.
Keywords
paclitaxel, hyperthermic intraperitoneal chemotherapy, tumour growth delay, beta-cyclodextrin, PERITONEAL CARCINOMATOSIS, CYTOREDUCTIVE SURGERY, OVARIAN-CANCER, COLORECTAL-CANCER, CREMOPHOR EL, CYCLODEXTRIN COMPLEXES, SYSTEMIC CHEMOTHERAPY, THERMAL ENHANCEMENT, RANDOMIZED-TRIAL, DRUG-DELIVERY

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 740.93 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bouquet-Geerardyn, Wim, Steven Deleye, Steven Staelens, Lieselotte De Smet, Nancy Van Damme, ISABELLE DEBERGH, Wim Ceelen, Filip De Vos, Jean Paul Remon, and Chris Vervaet. 2011. “Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an in Vivo Rat Model.” Pharmaceutical Research 28 (7): 1653–1660.
APA
Bouquet-Geerardyn, W., Deleye, S., Staelens, S., De Smet, L., Van Damme, N., DEBERGH, I., Ceelen, W., et al. (2011). Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. PHARMACEUTICAL RESEARCH, 28(7), 1653–1660.
Vancouver
1.
Bouquet-Geerardyn W, Deleye S, Staelens S, De Smet L, Van Damme N, DEBERGH I, et al. Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. PHARMACEUTICAL RESEARCH. 2011;28(7):1653–60.
MLA
Bouquet-Geerardyn, Wim, Steven Deleye, Steven Staelens, et al. “Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an in Vivo Rat Model.” PHARMACEUTICAL RESEARCH 28.7 (2011): 1653–1660. Print.
@article{2016386,
  abstract     = {To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-beta-cyclodextrin (Pac/RAME-beta-CD) versus TaxolA (R) at normo- and hyperthermic conditions in rats. 
Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment. 
PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-beta-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with TaxolA (R) did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia. 
Monitoring tumour growth via PET and MRI indicated that Pac/RAME-beta-CD inclusion complexes had a significantly higher efficacy compared to TaxolA (R) in a rat model for peritoneal carcinomatosis.},
  author       = {Bouquet-Geerardyn, Wim and Deleye, Steven and Staelens, Steven and De Smet, Lieselotte and Van Damme, Nancy and DEBERGH, ISABELLE and Ceelen, Wim and De Vos, Filip and Remon, Jean Paul and Vervaet, Chris},
  issn         = {0724-8741},
  journal      = {PHARMACEUTICAL RESEARCH},
  keyword      = {paclitaxel,hyperthermic intraperitoneal chemotherapy,tumour growth delay,beta-cyclodextrin,PERITONEAL CARCINOMATOSIS,CYTOREDUCTIVE SURGERY,OVARIAN-CANCER,COLORECTAL-CANCER,CREMOPHOR EL,CYCLODEXTRIN COMPLEXES,SYSTEMIC CHEMOTHERAPY,THERMAL ENHANCEMENT,RANDOMIZED-TRIAL,DRUG-DELIVERY},
  language     = {eng},
  number       = {7},
  pages        = {1653--1660},
  title        = {Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model},
  url          = {http://dx.doi.org/10.1007/s11095-011-0401-1},
  volume       = {28},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: